MedTrace Logo

Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms

NCT02775591 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 147

Last updated 2019-03-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether DA-9701(Motilitone) is effective and safe for the treatment on health-related quality of life in Parkinson's disease (PD) patients with gastrointestinal symptoms.

Conditions

  • Parkinson Disease
  • Dyspepsia

Interventions

DRUG

DA-9701

DA-9701 30mg Tablet

DRUG

DA-9701 placebo

Placebo pill manufactured to mask DA-9701 30mg Tablet

Sponsors & Collaborators

  • Samsung Medical Center

    collaborator OTHER

  • Korea University Guro Hospital

    collaborator OTHER

  • Hanyang University

    collaborator OTHER

  • Seoul Veterans Hospital

    collaborator OTHER

  • SMG-SNU Boramae Medical Center

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jee-Young Lee, MD, PhD · SMG-SNU Boramae Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-06-30
Completion
2018-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02775591 on ClinicalTrials.gov